155 related articles for article (PubMed ID: 8789063)
1. Targeting of chrolamphenicol acetyltransferase to human immunodeficiency virus particles via Vpr and Vpx.
Sato A; Isaka Y; Kodama M; Yoshimoto J; Kawauchi S; Kuwata T; Adachi A; Hayami M; Yoshi O; Fujiwara T
Microbiol Immunol; 1995; 39(12):1015-9. PubMed ID: 8789063
[TBL] [Abstract][Full Text] [Related]
2. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx.
Wu X; Liu H; Xiao H; Kim J; Seshaiah P; Natsoulis G; Boeke JD; Hahn BH; Kappes JC
J Virol; 1995 Jun; 69(6):3389-98. PubMed ID: 7745685
[TBL] [Abstract][Full Text] [Related]
3. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
Wu X; Liu H; Xiao H; Kappes JC
Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Vpr-chloramphenicol acetyltransferase fusion proteins: sequence requirement for virion incorporation and analysis of antiviral effect.
Yao XJ; Kobinger G; Dandache S; Rougeau N; Cohen E
Gene Ther; 1999 Sep; 6(9):1590-9. PubMed ID: 10490769
[TBL] [Abstract][Full Text] [Related]
5. Targeting a foreign protein into virion particles by fusion with the Vpx protein of simian immunodeficiency virus.
Park IW; Sodroski J
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):341-50. PubMed ID: 8601220
[TBL] [Abstract][Full Text] [Related]
6. Transactivation is a conserved function among primate lentivirus Vpr proteins but is not shared by Vpx.
Philippon V; Matsuda Z; Essex M
J Hum Virol; 1999; 2(3):167-74. PubMed ID: 10413368
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle inhibitory effects of HIV and SIV Vpr and Vpx in the yeast Schizosaccharomyces pombe.
Zhang C; Rasmussen C; Chang LJ
Virology; 1997 Mar; 230(1):103-12. PubMed ID: 9126266
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particles.
Wu X; Liu H; Xiao H; Conway JA; Kappes JC
J Virol; 1996 Jun; 70(6):3378-84. PubMed ID: 8648668
[TBL] [Abstract][Full Text] [Related]
9. Morphological study on biologically distinct vpx/vpr mutants of HIV-2.
Piroozmand A; Khamsri B; Fujita M; Adachi A; Uchiyama T
J Med Invest; 2006 Aug; 53(3-4):271-6. PubMed ID: 16953064
[TBL] [Abstract][Full Text] [Related]
10. Comparative study on the structure and cytopathogenic activity of HIV Vpr/Vpx proteins.
Khamsri B; Murao F; Yoshida A; Sakurai A; Uchiyama T; Shirai H; Matsuo Y; Fujita M; Adachi A
Microbes Infect; 2006 Jan; 8(1):10-5. PubMed ID: 16153874
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
12. Interaction with the p6 domain of the gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses.
Selig L; Pages JC; Tanchou V; Prévéral S; Berlioz-Torrent C; Liu LX; Erdtmann L; Darlix J; Benarous R; Benichou S
J Virol; 1999 Jan; 73(1):592-600. PubMed ID: 9847364
[TBL] [Abstract][Full Text] [Related]
13. Effects of mutant Vpr/Vpx on HIV-2 assembly demonstrated by immunoelectron microscopy.
Wan JJ; Ratner L
Proc Natl Sci Counc Repub China B; 2001 Jan; 25(1):50-8. PubMed ID: 11254173
[TBL] [Abstract][Full Text] [Related]
14. Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis.
Paxton W; Connor RI; Landau NR
J Virol; 1993 Dec; 67(12):7229-37. PubMed ID: 8230445
[TBL] [Abstract][Full Text] [Related]
15. Degradation of SAMHD1 by Vpx Is Independent of Uncoating.
Jáuregui P; Logue EC; Schultz ML; Fung S; Landau NR
J Virol; 2015 May; 89(10):5701-13. PubMed ID: 25762741
[TBL] [Abstract][Full Text] [Related]
16. A conserved dileucine-containing motif in p6(gag) governs the particle association of Vpx and Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm).
Accola MA; Bukovsky AA; Jones MS; Göttlinger HG
J Virol; 1999 Dec; 73(12):9992-9. PubMed ID: 10559313
[TBL] [Abstract][Full Text] [Related]
17. Protein stability influences human immunodeficiency virus type 2 Vpr virion incorporation and cell cycle effect.
Kewalramani VN; Park CS; Gallombardo PA; Emerman M
Virology; 1996 Apr; 218(2):326-34. PubMed ID: 8610459
[TBL] [Abstract][Full Text] [Related]
18. Evolution of the primate lentiviruses: evidence from vpx and vpr.
Tristem M; Marshall C; Karpas A; Hill F
EMBO J; 1992 Sep; 11(9):3405-12. PubMed ID: 1324171
[TBL] [Abstract][Full Text] [Related]
19. Differential apoptosis effects of primate lentiviral Vpr and Vpx in mammalian cells.
Chang LJ; Chen CH; Urlacher V; Lee TZ
J Biomed Sci; 2000; 7(4):322-33. PubMed ID: 10895056
[TBL] [Abstract][Full Text] [Related]
20. The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.
Kondo E; Mammano F; Cohen EA; Göttlinger HG
J Virol; 1995 May; 69(5):2759-64. PubMed ID: 7707498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
